An oral drug for the treatment of advanced melanoma in patients with BRAF V600E and V600K mutations.
If you have a Hayes login, click here to view the full report on the Knowledge Center.
Complete this form to request the full report.
Report Sale Policy: Hayes only sells reports to subscribers and to manufacturers of a health technology that is the subject of the report requested. Individuals requesting reports in response to a payment denial should contact the health insurer involved for details.
Please contact us if you are interested in a Hayes subscription.